ProQR Therapeutics $PRQR announced successful results in a Phase 1 proof-of-concept study, PQ-010-002, evaluating lead product candidate and Fast Track-tagged QR-010 in homozygous deltaF508 cystic fibrosis (CF) patients. The top-line data will be submitted on Thursday, October 27, 2016 at the North American Cystic Fibrosis Conference in Orlando, Florida.